Vivos Therapeutics, Inc - VVOS Short-Term Debt to Capital

Vivos Therapeutics (VVOS) is a recognized leader in developing non-invasive devices for treating apnea, as confirmed by the price chart where the indicator stands at 0.00. The business model relies on partnering with licensed oral appliance laboratories, while patent ownership ensures independence from suppliers. The growth strategy is based on close collaboration with private dental practices to implement respiratory correction systems.

For the non-surgical sleep apnea therapy leader Vivos Therapeutics (VVOS), the balance between leverage and equity determines the sustainable development of its proprietary CARE technology. By analyzing the short-term debt-to-equity ratio, investors assess the proportion of liabilities maturing within one year, which allows for the determination of liquidity risk and the efficiency of the company's working capital management.